<DOC>
	<DOCNO>NCT00099450</DOCNO>
	<brief_summary>The objective study look safety tolerability experimental drug , people process drug , drug affect people , identify dose dos study subsequent future study .</brief_summary>
	<brief_title>Study Tolerability , Pharmacokinetics , Pharmacodynamics INS50589 Intravenous Infusion Healthy Volunteers</brief_title>
	<detailed_description>The purpose trial determine administration INS50589 Intravenous Infusion well tolerate , determine pharmacological effect INS50589 different dos , identify appropriate dose later efficacy study . More specifically , objective : - Evaluate safety tolerability - Evaluate pharmacokinetics INS50589 major metabolite ( ) - Evaluate effect INS50589 platelet function various dose level - Evaluate potential relationship plasma concentration INS50589 various pharmacodynamic endpoint - Identify one dose level INS50589 future study</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>INS 50589</mesh_term>
	<criteria>Have body mass index ( BMI ) 18.5 kg/m2 35 kg/m2 body weight great 120 kg . If female , must pregnant lactating , childbearing potential sexually active , must use acceptable method birth control . Have clinically significant acute chronic disease ( e.g. , coronary artery disease , diabetes , chronic renal insufficiency , asthma ) . Have major surgery within eight week dose . Have overt viral illness within four week dose . Have tendency history family tendency bleeding . Have clinically significant abnormality clinical laboratory test ( chemistry , hematology , urinalysis ) . Have take aspirin nonsteroidal antiinflammatory drug ( NSAID ) within 10 day prior admission study facility . Have ever take receive following medical condition : ( antiplatelet compound include clopidogrel , ticlopidine , dipyridamole , tirofiban , eptifibatide , abciximab , adenosine , prostacyclin ) ( anticoagulant include vitamin K antagonist , thrombin inhibitor , heparin , hirudin related compound , argatroban factor Xa inhibitor ) Have clinically significant ECG abnormality .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>bleeding</keyword>
	<keyword>blood transfusion</keyword>
	<keyword>surgery</keyword>
</DOC>